JANE OBA
Projetos de Pesquisa
Unidades Organizacionais
Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
30 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 30
- Fatal Presentation of Thrombotic Cutaneous Gangrene Associated With Acute Severe Colitis(2023) BARROS, Luisa Leite; PRADO, Rita de Cassia Parente; FERREIRA, Lucas Fortes Portela; AZEVEDO, Matheus Freitas Cardoso de; OBA, Jane; CARLOS, Alexandre de Souza; DAMIAO, Aderson Omar Mourao Cintra
- Anti-TNF Therapy in Elderly Patients With Inflammatory Bowel Disease in a Tuberculosis-Endemic Country(2023) BARROS, Luisa Leite; AZEVEDO, Matheus Freitas Cardoso de; CARLOS, Alexandre de Souza; LOPES, Paula De Azevedo; FUJITA, Andre Okuhara; BRITO, Daniela Sanches; KAMADA, Daniela Midori; PRADO, Rita de Cassia Parente; ANDRADE, Julia Carvalho De; OBA, Jane; DAMIAO, Aderson Omar Mourao Cintra
- Prevalence of dysplasia and colorectal cancer in Ulcerative Colitis patients from a referral center in Latin America(2021) JUNIOR, R. S. F.; CARVALHO, M. F.; SILVA, J. C.; BARROS, L. L.; AZEVEDO, M. F. C.; CARLOS, A. D. S.; OBA, J.; HASHIMOTO, C. L.; CANCADO, E. L. R.; DAMIAO, A. O. M. C.; SIPAHI, A. M.
- Efficacy of Early Optimization of Infliximab Guided by Therapeutic Drug Monitoring during Induction-A Prospective Trial(2023) GARCIA, Karoline Soares; AZEVEDO, Matheus Freitas Cardoso de; CARLOS, Alexandre de Sousa; BARROS, Luisa Leite; OBA, Jane; SOBRADO JUNIOR, Carlos Walter; SIPAHI, Aytan Miranda; ALVES, Olivia Duarte de Castro; NAVARRO-RODRIGUEZ, Tomas; PARRA, Rogerio Serafim; CHEBLI, Julio Maria Fonseca; CHEBLI, Liliana Andrade; FLORES, Cristina; VIEIRA, Andrea; CEARA, Christianne Damasceno Arcelino do; QUEIROZ, Natalia Sousa Freitas; DAMIAO, Aderson Omar Mourao CintraTherapeutic drug monitoring (TDM) during induction therapy with anti-tumor necrosis factor drugs has emerged as a strategy to optimize response to these biologics and avoid undesired outcomes related to inadequate drug exposure. This study aimed to describe clinical, biological, and endoscopic remission rates at six months in Brazilian inflammatory bowel disease (IBD) patients following a proactive TDM algorithm guided by IFX trough levels (ITL) and antibodies to IFX (ATI) levels during induction, at week six. A total of 111 IBD patients were prospectively enrolled, excluding those previously exposed to the drug. ITL & GE; 10 & mu;g/mL was considered optimal. Patients with suboptimal ITL (<10 & mu;g/mL) were guided according to ATI levels. Those who presented ATI & LE; 200 ng/mL underwent dose intensification in the maintenance phase, and patients with ATI > 200 ng/mL discontinued IFX. In our study, proactive TDM was associated with persistence in the IFX rate at six months of 82.9%. At that time, rates of clinical, biological, and endoscopic remission in patients under IFX treatment were 80.2%, 73.9%, and 48.1%, respectively. Applying a simplified TDM-guided algorithm during induction seems feasible and can help improve patients' outcomes in clinical practice.
- Safety of anti-TNF introduction following tuberculosis treatment in Inflammatory Bowel Disease patients in an endemic area(2021) AZEVEDO, M. F. C. D.; JUSTUS, F. F.; LIMA, C. C. G.; GARCIA, K. S.; BARROS, L. L.; OBA, J.; CARLOS, A. D. S.; MILANI, L. R.; SIPAHI, A. M.; DAMIAO, A. O. M. C.; QUEIROZ, N. S. F.
- Active tuberculosis in inflammatory bowel disease patients: a case-control study(2023) AZEVEDO, Matheus Freitas Cardoso de; BARROS, Luisa Leite; JUSTUS, Filipe Fernandes; OBA, Jane; GARCIA, Karoline Soares; MARTINS, Camilla de Almeida; CARLOS, Alexandre de Sousa; LEITE, Andre Zonetti Arruda; SIPAHI, Aytan Miranda; QUEIROZ, Natalia Sousa Freitas; DAMIAO, Aderson Omar Mourao CintraBackground/Aims:Anti-tumor necrosis factor (anti-TNF) drugs have been the mainstay therapy for moderate to severe inflammatory bowel disease (IBD) over the past 25 years. Nevertheless, these drugs are associated with serious opportunistic infections like tuberculosis (TB). Brazil is ranked among the 30 countries with the highest incidence of TB in the world. This study aimed at identifying risk factors for the development of active TB and describing clinical characteristics and outcomes in IBD patients followed at a tertiary referral center in Brazil. Methods:We conducted a retrospective, case-control study between January 2010 and December 2021. Active TB cases in IBD patients were randomly matched 1:3 to controls (IBD patients with no previous history of active TB) according to gender, age, and type of IBD. Design:This was a retrospective, case-control study. Results:A total of 38 (2.2%) cases of TB were identified from 1760 patients under regular follow-up at our outpatient clinics. Of the 152 patients included in the analysis (cases and controls), 96 (63.2%) were male, and 124 (81.6%) had Crohn's disease. Median age at TB diagnosis was 39.5 [interquartile range (IQR) 30.8-56.3]. Half of the active TB cases were disseminated (50%). Overall, 36 patients with TB (94.7%) were being treated with immunosuppressive medications. Of those, 31 (86.1%) were under anti-TNF drugs. Diagnosis of TB occurred at a median of 32 months after the first dose of anti-TNF (IQR 7-84). In multivariate analysis, IBD diagnosis older than 17 years and anti-TNF therapy were significantly associated with the development of TB (p < 0.05). After the TB treatment, 20 (52.7%) patients received anti-TNF therapy, and only one developed 'de novo' TB 10 years after the first infection. Conclusions:TB remains a significant health problem in IBD patients from endemic regions, especially those treated with anti-TNFs. In addition, age at IBD diagnosis (>17 years old) was also a risk factor for active TB. Most cases occur after long-term therapy, suggesting a new infection. The reintroduction of anti-TNFs agents after the anti-TB treatment seems safe. These data highlight the importance of TB screening and monitoring in IBD patients living in endemic areas.
bookPart Avaliação da inflamação do trato gastrointestinal(2023) LIMA, Lívia Maria Lindoso; BIBAS, Mariana Deboni; OBA, Jane; JR, Alvaro PulchinellibookPart Dor abdominal(2021) OBA, Jane- BRAZILIAN CONSENSUS ON THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES IN PEDIATRIC PATIENTS: A CONSENSUS OF THE BRAZILIAN ORGANIZATION FOR CROHN’S DISEASE AND COLITIS (GEDIIB)(2022) LOMAZI, Elizete Aparecida; OBA, Jane; RODRIGUES, Maraci; MARMO, Michela Cynthia da Rocha; SANDY, Natascha Silva; SDEPANIAN, Vera Lucia; IMBRIZI, Marcello; BAIMA, Júlio Pinheiro; MAGRO, Daniéla Oliveira; ALBUQUERQUE, Idblan Carvalho de; ZABOT, Gilmara Pandolfo; CASSOL, Ornella Sari; SAAD-HOSSNE, RogérioABSTRACT Background: Approximately 25% of patients with inflammatory bowel disease (IBD) develop the disease during childhood or adolescence and treatment aims to control active symptoms and prevent long-term complications. The management of Crohn’s disease (CD) and ulcerative colitis (UC) can be especially challenging in children and adolescents, related to particularities that may affect growth, development, and puberty. Objective: This consensus aims to provide guidance on the most effective medical and surgical management of pediatric patients with CD or UC. Methods: Experts in Pediatric IBD representing Brazilian gastroenterologists (Brazilian Organization for Crohn’s Disease and Colitis [GEDIIB]) developed this consensus. A rapid review was performed to support the recommendations/statements. Medical and surgical recommendations were structured and mapped according to the disease type, disease activity, and indications and contraindications for medical and surgical treatment. After structuring the statements, the modified Delphi Panel methodology was used to conduct the voting. The process took place in three rounds: two using a personalized and anonymous online voting platform and one face-to-face. Whenever participants did not agree with a specific recommendation, an option to explain why was offered to enable free-text responses and provide the opportunity for the experts to elaborate or explain disagreement. The consensus of recommendations in each round was accepted when reached ≥80% agreement. Results and conclusion: The recommendations are presented according to the stage of treatment and severity of the disease in three domains: management and treatment (drug and surgical interventions), criteria for evaluating the effectiveness of medical treatment, and follow-up/ patient monitoring after initial treatment, follow-up/ patient monitoring after initial treatment. Surgical recommendations were grouped according to disease type and recommended surgery. The target audience for this consensus was general practitioners, gastroenterologists, and surgeons interested in the treatment and management of pediatric CD and UC. Additionally, the consensus aimed to support the decision-making of health insurance companies, regulatory agencies, and health institutional leaders and/or administrators.
conferenceObject Inflammatory Bowel Diseases and Autoimmune Hepatitis: Is Anti-TNF Therapy an Option?(2019) ROCHA, Beatriz; QUEIROZ, Natalia; AZEVEDO, Matheus; ALEXANDRE, Carlos; MILANI, Luciane; CANCADO, Eduardo; TERRABUIO, Debora; BARROS, Luisa; OBA, Jane; LEITE, Andre; SIPAHI, Aytan; DAMIAO, Aderson
- «
- 1 (current)
- 2
- 3
- »